Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
MALDI-TOF MS Analysis of Nanotrap Enriched Low Molecular Weight Proteins from Human Serum
MALDI-TOF MS Analysis of Nanotrap® Enriched Low Molecular Weight Proteins from Human Serum DESCRIPTION Biomarkers are often masked by high abundant proteins or may be susceptible to proteolysis Illustrated here is the ability to enrich low abundant, low molecular weight proteins directly from serum while excluding high molecular weight proteins The ability to differentially trap proteins based on bait chemistry is also examined...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.